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The reevaluation of the genus Trichosporon has led to the replacement of the old taxon Trichosporon beigelii
by six new species. Sequencing of the ribosomal DNA (rDNA) intergenic spacer 1 (IGS1) is currently man-
datory for accurate Trichosporon identification, but it is not usually performed in routine laboratories. Here we
describe Trichosporon species distribution and prevalence of Trichosporon asahii genotypes based on rDNA
IGS1 sequencing as well as antifungal susceptibility profiles of 22 isolates recovered from blood cultures. The
clinical isolates were identified as follows: 15 T. asahii isolates, five Trichosporon asteroides isolates, one
Trichosporon coremiiforme isolate, and one Trichosporon dermatis isolate. We found a great diversity of different
species causing trichosporonemia, including a high frequency of isolation of T. asteroides from blood cultures
that is lower than that of T. asahii only. Regarding T. asahii genotyping, we found that the majority of our
isolates belonged to genotype 1 (86.7%). We report the first T. asahii isolate belonging to genotype 4 in South
America. Almost 50% of all T. asahii isolates exhibited amphotericin B MICs of >2 g/ml. Caspofungin MICs
obtained for all the Trichosporon sp. isolates tested were consistently high (MICs > 2 g/ml). Most isolates
(87%) had high MICs for 5-flucytosine, but all of them were susceptible to triazoles, markedly to
voriconazole (all MICs < 0.06 g/ml).
The incidence of invasive mycoses caused by emergent fun-
gal pathogens has risen considerably over the last two decades.
This fact is related to several factors, including the increased
occurrence of degenerative and malignant diseases in different
populations, as well as the higher number of patients exposed
to organ transplantation, immunosuppressive therapies, che-
motherapy, broad-spectrum antibiotics, and invasive medical
procedures. It is important to emphasize that emergent fungal
infections are usually difficult to diagnose, refractory to con-
ventional antifungal drugs, and associated with high mortality
rates (8, 10, 26, 32, 34, 47, 51).
Invasive infections caused by Trichosporon spp. are reported
mostly for cancer patients that have central venous catheters
(22, 50–52). Although trichosporonemia represents a small
percentage of all fungal invasive infections, Trichosporon spp.
have been reported as the second- or third-most-common
agents of yeast fungemia (13, 21, 51).
Phenotypic methods for Trichosporon species identification
usually generate inconsistent results, and none of the commer-
cial tests available include the whole new taxonomic categories
in their databases (1, 36, 37). For instance, it has been men-
tioned in the literature that an isolate identified by molecular
methods as Trichosporon dermatis was mistakenly identified as
Trichosporon mucoides when Vitek Systems 1 and 2 (Bio-
Me´rieux, France) were used (16). Furthermore, Ahmad et al.
(1) reported that four isolates previously identified by Vitek 2
as Trichosporon asahii were identified as Trichosporon aster-
oides by molecular techniques. There is a consensus that mo-
lecular methods are required for accurate identification of this
genus, but they are still costly and not suitable for most routine
laboratories (38, 42).
Currently, the genus Trichosporon includes the following
species as potential human pathogens: Trichosporon cutaneum,
T. asahii, T. asteroides, T. mucoides, Trichosporon inkin, Tricho-
sporon jirovecii, T. dermatis, Trichosporon domesticum, Tricho-
sporon montevideense, Trichosporon japonicum, Trichosporon
coremiiforme, Trichosporon faecale, and Trichosporon loubieri
(7, 34, 38). Sugita et al. (42) reported that the ribosomal DNA
(rDNA) internal transcribed spacer (ITS) region is not suit-
able for Trichosporon species identification. Therefore, the
analysis of the rDNA intergenic spacer (IGS) region is a
crucial method which should be used to distinguish phylo-
genetically closely related species (42–44).
Considering the limitations of routine laboratories in con-
ducting appropriate identification of Trichosporon spp., there is
a lack of data for species distribution and antifungal suscepti-
bility of hematogenous infections caused by this particular
genus. Girmenia et al. (15) published the largest retrospective
clinical study of invasive trichosporonosis documented during
a period of 20 years. Despite representing the largest series of
invasive trichosporonosis ever published before, only 30 of 287
isolates were identified to the species level.
Several authors have attempted to evaluate the antifungal
susceptibilities of Trichosporon spp. but most of them still used
the old nomenclature T. beigelii (17, 35, 48, 49). Antifungal
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susceptibilities of bloodstream isolates belonging to this genus
have not yet been largely investigated. Rodriguez-Tudela et al.
(38) performed antifungal susceptibility testing for Trichos-
poron spp. accurately identified by rDNA IGS1 region se-
quencing. However, only 9 out of 49 strains were recovered
from bloodstream infections (BSI). Thereafter, the same group
published a paper investigating T. asahii susceptibility testing
(39), but once again, only 8 out of 18 isolates were recovered
from BSI. To date, only limited data are available for species
distribution and antifungal susceptibilities of BSI isolates of
Trichosporon spp. accurately identified by molecular tools.
In the present study, we investigated species distribution and
antifungal susceptibilities of 22 bloodstream Trichosporon iso-
lates sequentially recovered from different patients hospital-
ized in five medical centers between 1995 and 2007.
MATERIALS AND METHODS
Strains. We evaluated a total of 22 Trichosporon sp. bloodstream isolates
sequentially obtained from different patients admitted to five tertiary care hos-
pitals in Sao Paulo, Brazil, between January 1995 and December 2004. The
isolates were stored on 1% yeast extract, 2% peptone, 2% dextrose, and 3%
glycerol at 70°C. Of note, the isolates mentioned above were collected during
multicentric surveillance studies of fungemia coordinated by our group (9, 10).
The isolates were identified to the species level by sequencing the rDNA IGS1
region and were subsequently submitted to antifungal susceptibility testing by
standard methods. Candida parapsilosis (ATCC 22019) and Candida krusei
(ATCC 6258) were used as quality control strains for antifungal susceptibility
testing. T. asahii (CBS 2479 and CBS 2530), T. mucoides (CBS 7625), T. inkin
(CBS 5585), T. asteroides (CBS 2481), and T. ovoides (CBS 7556) were used as
control strains for Trichosporon molecular identification. As negative controls,
Candida albicans (ATCC 90028) and C. parapsilosis (ATCC 22019) were used to
check for the specificity of Trichosporon-specific oligonucleotides. The isolates
used in the present study are displayed in Table 1.
Screening of Trichosporon isolates by conventional methods. Yeast isolates
were obtained from blood cultures from the referred medical centers by using
either Bactec 9000 (BD) or BacT/Alert 3D (BioMe´rieux, France). Yeast isolates
from original cultures were plated onto CHROMagar Candida (CHROMagar
Microbiology, Paris, France) to check for purity and viability. All strains able to
produce arthroconidia, as revealed by their micromorphology on corn meal-
Tween 80 agar, and able to hydrolyze urea were considered to belong to the
genus Trichosporon and were further identified by molecular techniques (http:
//www.cbs.knaw.nl/databases) (3, 11, 18, 23, 38, 40).
DNA extraction. The isolates were grown in Falcon tubes containing 2 ml yeast
extract-peptone-dextrose medium for 16 h, 30°C at 200 rpm in a gyrator with
shaking for 48 h. DNA was extracted using the fast small-scale isolation protocol
described elsewhere (27). RNA was removed by treatment with RNase A (Phar-
macia) for 1 h at 37°C. DNA concentration and purity were determined by
optical density at 260 nm and ratio optical density at 260/280 nm, respectively.
PCR assay and IGS1 region sequencing. To confirm the correct genus iden-
tification, the primer pair TRF (5-AGAGGCCTACCATGGTATCA-3) and
TRR (5-TAAGACCCAATAGAGCCCTA-3) was used (44). The samples
were amplified in a Thermocycler (model 9600; Applied Biosystems) by using the
following cycling parameters: one initial cycle of 94°C for 3 min, followed by 30
cycles of 1 min at 94°C, 1 min at 55°C, and 1 min at 72°C and a final cycle of 5
min at 72°C. For the accurate identification of Trichosporon strains to the species
level, the IGS1 region was amplified by PCR using the following primer pair: 26F
(5-ATCCTTTGCAGACGACTTGA-3) and 5SR (5-AGCTTGACTTCGCAG
ATCGG-3) and 2 PCR Master Mix (Promega). PCR was performed with one
initial cycle of 94°C for 5 min, followed by 40 cycles of 1 min at 94°C, 1 min at
57°C, and 2 min at 72°C and a final cycle of 5 min at 72°C. PCR products were
sequenced by using the dideoxynucleotide method in an ABI Prism 3100 auto-
mated sequencer (Applied Biosystems, CA). The sequencing reaction included
the primer pair 26F and 5SR (42) and the BigDye Terminator reagent kit
(Applied Biosystems, CA) and was performed according to the manufacturer’s
instructions. Nucleotide sequences were submitted for BLAST analysis at the
NCBI site (http://www.ncbi.nlm.nih.gov) for species identification. Only se-
quences deposited in GenBank showing high similarities with our query se-
quences and an E value of lower than 105 were used in this study.
Phylogenetic analysis. Sequences were aligned using BioEdit software (v7.09).
Aligned sequences were used for phylogenetic analysis conducted with Mega 4.1
Beta Software (v4.1 Beta). The method used for tree constructions was the
unweighted-pair group method using average linkages (UPGMA). Phylogram
stability was accessed by bootstrapping with 1,000 pseudoreplications. To root
the phylogenetic tree for all the Trichosporon isolates, the IGS1 sequences of
Cryptococcus neoformans (GenBank accession number EF211300) and Crypto-
coccus gatii (GenBank accession number EF211336) were used as outgroups.
In vitro susceptibility testing. Antifungal susceptibility testing was performed
using the broth microdilution assay according to an adaptation of the method-
ology recommended for Candida spp. and Cryptococcus neoformans and accord-
ing to CLSI approved standard M27-A2 (31). The following antifungal drugs,
supplied by the manufacturers as pure standard compounds, were tested at the
indicated concentration ranges: amphotericin B (AMB), 0.015 to 8 g/ml (Sigma
Chemical Corporation, St. Louis, MO); 5-flucytosine (5FC), 0.125 to 64 g/ml
(Sigma Chemical Corporation, St. Louis, MO); itraconazole (ITC), 0.03 to 16
g/ml (Janssen Pharmaceutical, Titusville, NJ); fluconazole (FLC), 0.125 to 64
g/ml; voriconazole (VRC), 0.03 to 16 g/ml (Pfizer Incorporated, New York,
NY); and caspofungin (CAS), 0.03 to 16 g/ml (Merck Research Laboratories,
NJ). Briefly, the medium used was RPMI-1640 with L-glutamine, without bicar-
bonate, buffered at pH 7.0 with 0.165 M morpholinepropanesulfonic acid. The
yeast inoculum suspension was prepared using a spectrophotometer to obtain a
final yeast concentration of 0.5  103 to 2.5  103 cells/ml in each well of the
microtiter plate. The assays were incubated at 35°C. Cell cultures were incubated
for 48 h as suggested by Brito et al. (6). Quality control strains (C. parapsilosis
ATCC 22019 and C. krusei ATCC 6258) were included on each day of the assay
to check the accuracy of the drug dilutions and the reproducibility of the results.
The MIC endpoint for AMB was considered the lowest tested drug concentra-
tion able to prevent any visible growth. The MIC for triazoles, CAS, and 5FC was
considered the lowest tested drug concentration causing a significant reduction
(approximately 50%) in growth compared to the growth of the drug-free positive
control (31).
Statistical analysis. Differences in mortality rates between adults and infants
were analyzed by Fisher’s test. P values of 0.05 were considered significant for
all the statistics analyzed.
GenBank accession numbers. GenBank accession numbers were as follows:
EU934801, EU934808, EU934809, EU934810, EU938047, EU980326, EU938049,
EU938050, EU938051, EU938052, EU938054, EU938055, EU938056, EU938058,
EU934803, EU934811, EU938046, EU934802, EU934800, EU938059, EU938048,
EU938053, EU938057, EU934807, EU934804, EU934805, EU934806, and
EU938060.
RESULTS
Demographic and clinical data. We were able to collect
clinical information for 18 of 22 patients with Trichosporon
invasive infections. Our series was represented by pediatric
(44%) and adult patients exhibiting a large variety of un-
derlying conditions, including premature birth, surgery, or-
gan failures, inflammatory gastrointestinal disease, and can-
cer, who frequently developed systemic bacterial infections
(67%) and had a central venous catheter in place at the
onset of fungemia. Mortality rates of infants were signifi-
cantly lower than those for adults (30% against 87.5%, re-
spectively; P  0.025) (Table 1).
Molecular identification of Trichosporon isolates. To dou-
ble-check for accurate identification of the genus, we per-
formed diagnostic PCR using primers TRR and TRF (44).
This pair of primers is Trichosporon specific and amplifies part
of the nucleotide sequences of the rDNA small subunit (18S).
DNA bands of approximately 170 bp were obtained for all the
isolates tested and for Trichosporon reference strains (data not
shown). In addition, there was no amplification of DNA iso-
lated from Candida spp. (negative control). Therefore, our
strains were confirmed to be Trichosporon spp.
For species identification, DNA fragments of the IGS1 re-
gion were amplified and DNA sequences obtained were sent to
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the GenBank genome database at the NCBI website (http:
//ncbi.nlm.nih.gov) using BLAST to compare gene sequences.
All the Trichosporon control strains were unambiguously iden-
tified by sequencing. This fact, together with an E value of 0 for
all the BLAST matches, supported our accurate final identifi-
cation. The 22 clinical isolates were identified as follows: 15 T.
asahii isolates, five T. asteroides isolates, one T. coremiiforme
isolate, and one T. dermatis isolate (Table 1).
Phylogenetic analysis. UPGMA analysis using 1,000 pseu-
doreplications of the IGS1 region sequences of the isolates, as
well as reference strains, adequately resolved all Trichosporon
species (Fig. 1). The results obtained by our phylogenetic anal-
ysis reinforce the accurate molecular identification in the
present study.
All T. asahii isolates clustered together, although minor
differences were observed between isolates related to their
genetic relatedness (Fig. 1). We decided to further investi-
gate this genetic variability within the species. We con-
structed a phylogenetic tree using the UPGMA method
including rDNA IGS1 sequences of our T. asahii isolates
and a representative sequence of each T. asahii genotype
described by Sugita et al. (42) and Rodriguez-Tudela et al.
(39) deposited in GenBank. We found that the majority of
our isolates belonged to genotype 1 (86.7%), while one
FIG. 1. Rooted phylogenetic tree of Trichosporon clinical isolates based on confidently aligned IGS1 rDNA sequences and obtained by
UPGMA analysis and 1,000 bootstrap simulations.
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isolate belonged to genotype 3 and another isolate belonged
to genotype 4 (Fig. 2). Here we describe the first T. asahii
isolate belonging to genotype 4 from South America. Un-
fortunately, we could not include genotype 6 in our analysis
because IGS1 sequences for this genotype were not avail-
able from the GenBank database.
Interestingly, the only T. coremiiforme isolate found in our
study shares a common branch with T. asahii, with a bootstrap
support higher than 90, indicating high phylogenetic relation
(Fig. 1). All T. asteroides isolates clustered together and
showed high genetic relatedness within the group (bootstrap
99) and share a common branch with T. asahii and T. coremi-
iforme (bootstrap  99). We have included in our sequencing
analysis one isolate each of reference strains T. inkin and T.
ovoides (CBS 5585 and 7556, respectively). The two species
clustered together within the same clade (bootstrap  99),
demonstrating high phylogenetic relation. Another highly re-
lated cluster was composed of T. dermatis and T. mucoides,
showing a bootstrap support of 99 (Fig. 1).
Antifungal susceptibility testing. MICs of the 22 strains of
Trichosporon spp. tested ranged from 0.25 to 4 g/ml for AMB,
0.125 to 8 g/ml for FLC, 0.03 to 0.125 g/ml for ITC, 0.03 to
0.06 g/ml for VRC, 0.5 to 64 g/ml for 5FC, and 2 to 16
g/ml for CAS. Table 2 summarizes ranges and geometric
FIG. 2. Rooted phylogenetic tree of Trichosporon asahii IGS1 genotypes based on confidently aligned sequences and obtained by UPGMA
analysis and 1,000 bootstrap simulations.
TABLE 2. In vitro activity of six antifungal agents against 22 Trichosporon sp. strains tested by CLSI microdilution assay
Trichosporon sp. (no.
of isolates)
Cell
incubation
period (h)
MIC (g/ml) for indicated antifungal agenta
AMB FLC ITC VRC 5FC CAS
Range GM Range GM Range GM Range GM Range GM Range GM
T. asahii (15) 24 0.5–2 0.9 0.25–2 0.8 0.03–0.125 0.07 0.03–0.06 0.03 0.5–32 12.1 2–16 14.6
48 0.5–4 1.4 0.25–8 1.3 0.03–0.125 0.08 0.03–0.06 0.03 4–64 27.9 16–16 16
T. asteroides (5) 24 0.25–1 1 0.125–0.5 0.3 0.03–0.125 0.05 0.03–0.06 0.03 0.5–32 8 2–16 10.6
48 0.5–4 1.5 0.5–1 0.8 0.03–0.125 0.06 0.03–0.06 0.03 4–64 16 16–16 16
T. dermatis (1) 24 0.5 0.5 0.06 0.06 8 16
48 0.5 0.5 0.06 0.06 16 16
T. coremiiforme (1) 24 0.5 0.125 0.06 0.03 2 8
48 1 1 0.125 0.03 16 16
a GM, geometric mean.
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means of MICs obtained for Trichosporon sp. isolates against
the six antifungal drugs tested.
Of note, 47% of all T. asahii isolates exhibited AMB MICs
of 2 g/ml. CAS MICs obtained for all the Trichosporon sp.
isolates tested were consistently high (MIC  2 g/ml). Most
isolates (87%) had high MICs for 5FC. With regard to the
azoles, the three drugs tested were active against all the spe-
cies, while VRC was the most effective antifungal agent. All the
isolates had MICs of 0.06 g/ml.
DISCUSSION
This report represents the largest published series address-
ing species distribution, prevalence of T. asahii genotypes and
antifungal susceptibility profiling of Trichosporon bloodstream
isolates accurately identified to the species level by using
rDNA IGS1 sequencing.
Surprisingly, in contrast to previously published data, cancer
and neutropenia were both present in a limited number of
patients (15, 26). Most of our patients were individuals with
several underlying associated conditions, such as premature
birth, surgery, burns, organ failure, and gastrointestinal inflam-
matory disease. Of note, 12 of 18 patients (67%) had an epi-
sode of systemic bacterial infection previously or concomi-
tantly to the fungemia. As expected, all patients had a central
venous catheter in place at the time of the diagnosis. This
finding reinforces the concept that invasive Trichosporon infec-
tions may occur in non-cancer patients who present chronic
illness and disruption of skin and mucous membranes (12).
Crude mortality was significantly higher for adults than for
infants.
In our study, we have found that the vast majority of the
isolates were identified as T. asahii (approximately 68%) (Ta-
ble 1). T. asahii has extensively been recognized as an emer-
gent agent of fungal invasive infections worldwide (4, 5, 19, 20,
28, 30, 46, 51, 53). The largest multicentric restrospective study
addressing Trichosporon invasive infections found that T. asahii
accounted for 15 of 30 isolates (50%) identified to the species
level (15). In the series of 49 Trichosporon isolates published by
Rodriguez-Tudela et al. (38), 15 strains were identified as T.
asahii by using IGS1 region sequencing, including eight of nine
Trichosporon isolates recovered from BSI. Considering the dif-
ficulties for routine laboratories in correctly identifying Tricho-
sporon spp., the true prevalence of fungemia due to T. asahii
may not be accurately estimated. In terms of antifungal sus-
ceptibility, in accordance with previously published data, a
significant number of T. asahii strains exhibited poor suscep-
tibility to AMB but good in vitro susceptibility to triazoles (2,
14, 33, 49, 54).
Surprisingly, T. asteroides was found to be the second-most-
common species isolated from BSI due to Trichosporon spp. in
our study (approximately 23%) (Table 1), while the isolates did
not originate from the same institution (therefore not being
characterized as an outbreak). T. asteroides is a causative agent
of superficial infections (42). The first case report of dissemi-
nated infection due to this agent was published in 2002, de-
scribing an intensive care unit female patient with multiple
organ failure and T. asteroides-positive cultures of blood, urine,
aspiration fluid, and catheter tip swabs (22). Ahmad et al. (1)
reported the isolation of three T. asteroides strains recovered
from blood and one from a catheter tip swab. However, it is
important to emphasize that both studies used the rDNA ITS
region for Trichosporon sp. identification, a method recently
replaced by rDNA IGS1 sequencing (42). In our series, except
for one strain of T. asteroides that had an AMB MIC of 4
g/ml, all the other clinical isolates of this species were sus-
ceptible to AMB, FLC, ITC, and VRC.
There are very few published instances where T. coremi-
iforme is described as the cause of human diseases. Interest-
ingly, despite the fact that Sugita et al. (42) refer to this species
as nonpathogenic, the T. coremiiforme type strain (CBS 2482)
was originally isolated from a patient with a fungal lesion of the
head. Recently, T. coremiiforme has been isolated from subcu-
taneous abscesses and urine (38). To our knowledge, the
present case represents the first report of a BSI caused by T.
coremiiforme.
We also recovered in our series an isolate of T. dermatis
from blood (Table 1). T. dermatis has been associated mostly
with superficial infections (16). The series of Rodriguez-
Tudela et al. (38) documented eight cases of T. dermatis caus-
ing infections. However, only one of these isolates was recov-
ered from blood, while all the others were isolated from the
skin, nails, and subcutaneous lesions of patients. A recent
paper published by Gunn et al. (16) documented a case of
trichosporonosis due to T. dermatis in a 13-month-old male
with a history of autoimmune enteropathy under immunosup-
pressant therapy, maintained with total parenteral nutrition
through a central venous catheter. The isolate was initially
misidentified as T. mucoides after sequencing the ITS region. It
is important to emphasize that T. dermatis is phylogenetically
closely related to T. mucoides and cannot be distinguished
when ITS sequences are used for comparison. Of note, in
contrast to T. dermatis, T. mucoides has been associated mostly
with invasive infection (16). Therefore, previously published
data on trichosporonemia must have miscalculated the number
of BSI which could have been caused by T. dermatis. This fact
emphasizes the necessity of correctly identifying Trichosporon
spp. by using rDNA IGS1 sequencing in order to avoid under-
estimation of the prevalence of a recently considered emergent
species.
Sequence polymorphisms are important to characterize strains
and assess their relatedness to genotypic levels, a relevant step
employed in epidemiologic studies of all microorganisms (41). In
the present study, we investigated sequence polymorphisms of the
IGS1 region of 15 T. asahii BSI strains. In a series of 18 isolates
from Spain, Argentina, and Brazil, in addition to 43 sequences
deposited in GenBank, Rodriguez-Tudela et al. (39) observed
that six different genotypes of T. asahii can be detected, instead
of the five genotypes previously described for this species by
Sugita et al. (42). Here we describe that the majority of our T.
asahii isolates (approximately 87%) belonged to genotype 1
(Fig. 2). These data corroborate the findings of Sugita et al.
(42). When characterizing the genotypes of 43 strains of T.
asahii, the authors also reported a predominance of genotype
1 within Japanese isolates (a prevalence of 87%). In addition,
Rodriguez-Tudela et al. (39) found that genotype 1 accounted
for 57.3% of the isolates obtained from South and North
America, China, and Japan. The prevalence of genotype 1
among Trichosporon isolates in three different series suggests a
worldwide predominance of this genotype among superficial
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and invasive cases of trichosporonosis. Further investigations
including a larger number of strains are necessary to confirm
this finding.
We document the first description of T. asahii genotype 4 in
South America. Until the present study, strains belonging only
to genotypes 1, 3, and 6 have been described for this continent
(39). Sugita et al. (42) reported that genotypes 2 and 4 were
detected only in Japan. However, Rodriguez-Tudela et al. (39)
inferred that all genotypes may be found in all geographic
regions. Until the present moment, genotype 2 has not been
described in South America. As reported by Rodriguez-Tudela
et al. (39), this genotype differs from genotype 1 by only one
nucleotide (thymine instead of adenine), suggesting a likely
recent evolution of genotype 2 in Japan.
We found high genetic relatedness of our T. coremiiforme
isolate and the T. asahii cluster (Fig. 1). Indeed, T. coremi-
iforme was considered for a long time to be a variety of T.
asahii (45). Despite the fact that the two species are almost
indistinguishable (99.7% similarity), when ITS region se-
quences are used for comparisons, the IGS1 regions of T.
coremiiforme and T. asahii are 78.8% similar (42). Therefore,
they should be considered different species.
We state here that all T. asteroides isolates were included in
the same cluster, sharing a common branch with T. asahii and
T. coremiiforme (Fig. 1). Of note, T. asteroides and T. asahii
DNA sequences are similar by 98.7% (for the ITS region) and
75.1% (for the IGS1 region) (42). It is important to emphasize
that all three species mentioned above belong to the same
clade (ovoides), according to the taxonomic classification of
the genus Trichosporon proposed by Middelhoven et al. (29).
In addition, the two reference strains, T. inkin and T. ovoides,
which clustered together and presented a high bootstrap (99)
also belong to the clade ovoides (29).
Finally, the clinical isolates T. dermatis and T. mucoides
shared the same cluster with a high bootstrap (99). As men-
tioned before, both species have undistinguishable ITS se-
quences and biochemical assimilation profiling (16). They be-
long to the clade cutaneum, according to the classification of
Middelhoven et al. (29).
This paper reinforces the relevance of correctly identifying
and testing Trichosporon BSI isolates with different antifungal
compounds. We have documented the great diversity of dif-
ferent species causing fungemia and a high frequency of T.
asteroides isolation from blood, a frequency lower than that of
T. asahii only. The different Trichosporon species also exhibited
peculiar in vitro antifungal susceptibility profiles, including a
significant number of T. asahii isolates showing low suscepti-
bility to AMB. T. asahii genotype 1 was confirmed to be the
most prevalent agent of T. asahii invasive infections in Brazil,
as published elsewhere. However, other genotypes can occur in
South America, such as genotype 4, as described in the present
study. Further investigations using a larger number of Tricho-
sporon isolates identified by molecular methods will contribute
to the understanding of the epidemiology and species distri-
bution of the genus worldwide.
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